![]() | This article is rated Stub-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Obinutuzumab.
|
This article is very out of date.
1. It makes no mention of a positive phase III study --published in 2017!-- and subsequent worldwide approvals in 1L follicular lymphoma.
2. It might also be updated to reflect another recent positive phase III study in 1L CLL
Preliminary : ASCO: Antibody Boosts Chemo in CLL. June 2013. aka GA101 - Rod57 ( talk) 07:12, 9 July 2013 (UTC)
All trials using obinutuzumab shows 70 trials. Some completed for which there should be some announcements or published results. - Rod57 ( talk) 01:56, 4 March 2016 (UTC)
I removed the content below from the article and put it here. This is not appropriately sourced and the content cannot stand in WP like this. Parking it here for now.
In 2014, the National Cancer Institute published the results of an international randomized phase III study in which they investigated the use of obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL) and other health conditions. When these patients were given obinutuzumab in combination with chlorambucil, a chemotherapeutic agent, they were found to live longer without their CLL progressing than patients who received only chlorambucil. The patients that received this combination therapy were more likely to go into complete remission as well as have better overall survival than those who received chlorambucil alone. In this study, they also compared patients treated with obinutuzumab and chlorambucil to patients that were treated with rituximab and chlorambucil. [1] When comparing CLL patients that received the obinutuzumab combination therapy versus the rituximab combination therapy, the researchers found that the obinutuzumab patients had higher rates of complete remission as well as longer progression-free survival. [1]
In a phase I study, the researchers are investigating the use of obinutuzumab in combination with venetoclax, a small molecule Bcl-2 inhibitor, to determine if this combination is more effective at treating CLL than obinutuzumab with chlorambucil. [2] [3]
Another study is investigating the use of obinutuzumab with lenalidomide, an antineoplastic agent, in non-Hodgkins lymphomas (NHL). [4]
References
- Jytdog ( talk) 13:44, 4 March 2016 (UTC)
Maybe in a new section mention :
![]() | This article is rated Stub-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Obinutuzumab.
|
This article is very out of date.
1. It makes no mention of a positive phase III study --published in 2017!-- and subsequent worldwide approvals in 1L follicular lymphoma.
2. It might also be updated to reflect another recent positive phase III study in 1L CLL
Preliminary : ASCO: Antibody Boosts Chemo in CLL. June 2013. aka GA101 - Rod57 ( talk) 07:12, 9 July 2013 (UTC)
All trials using obinutuzumab shows 70 trials. Some completed for which there should be some announcements or published results. - Rod57 ( talk) 01:56, 4 March 2016 (UTC)
I removed the content below from the article and put it here. This is not appropriately sourced and the content cannot stand in WP like this. Parking it here for now.
In 2014, the National Cancer Institute published the results of an international randomized phase III study in which they investigated the use of obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL) and other health conditions. When these patients were given obinutuzumab in combination with chlorambucil, a chemotherapeutic agent, they were found to live longer without their CLL progressing than patients who received only chlorambucil. The patients that received this combination therapy were more likely to go into complete remission as well as have better overall survival than those who received chlorambucil alone. In this study, they also compared patients treated with obinutuzumab and chlorambucil to patients that were treated with rituximab and chlorambucil. [1] When comparing CLL patients that received the obinutuzumab combination therapy versus the rituximab combination therapy, the researchers found that the obinutuzumab patients had higher rates of complete remission as well as longer progression-free survival. [1]
In a phase I study, the researchers are investigating the use of obinutuzumab in combination with venetoclax, a small molecule Bcl-2 inhibitor, to determine if this combination is more effective at treating CLL than obinutuzumab with chlorambucil. [2] [3]
Another study is investigating the use of obinutuzumab with lenalidomide, an antineoplastic agent, in non-Hodgkins lymphomas (NHL). [4]
References
- Jytdog ( talk) 13:44, 4 March 2016 (UTC)
Maybe in a new section mention :